Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Aspirin may Help Reduce Risk of Common Type of Breast Cancer

By Biotechdaily staff writers
Posted on 14 May 2008
Taking aspirin on a daily basis may lower women's risk of a specific type of breast cancer.

According to recent findings published in May 2008 BioMed Central's open access journal Breast Cancer Research, aspirin use was linked to a small reduction in estrogen receptor-positive breast cancers. More...
However, unlike some previous studies, aspirin and related painkillers were not found to lower the total risk of breast cancer.

Approximately 75% of breast cancers are estrogen receptor-positive (ER+), which means the cancer cells have receptors for the female hormone estrogen on their surface. Estrogen helps the cancer cells grow, therefore agents that block the action of estrogen are frequently used to treat ER+ cancer.

It is possible, in theory, that aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) could reduce the total risk of breast cancer. They block an enzyme called cyclooxygenase, an activity that could disrupt breast cancer development in a variety of ways--for example, by reducing the amount of estrogen produced in the body.

A US research team led by Dr. Gretchen Gierach from the University of Pittsburgh (PA, USA), assessed over 127,000 women enrolled in the National Institutes of Health [NIH; Bethesda, MD, USA]-AARP [American Association of Retired Persons] Diet and Health Study. The study participants were women aged 51-72 with no history of cancer.

Unlike other NSAIDs, aspirin has irreversible effects on cyclooxygenase (COX) enzymes, so the investigators looked for differences in cancer development according to whether women used aspirin or another kind of NSAID. NSAID use was not linked to total risk of breast cancer in this study. However, when the team considered different cancer subtypes and specific types of NSAIDs, they found that daily aspirin use was associated with a small reduction (16%) in the risk of ER+ breast cancer. A similar link was not seen in cases of ER- breast cancer.

Dr. Gierach concluded, "In summary, our results do not support an important influence of NSAIDs on total breast cancer risk. Daily aspirin use, however, appeared to offer some protection for ER+ breast cancer in this population. …Our results provide support for further evaluating relationships in prospective studies with well-defined measures of NSAID use by NSAID type… and by ER status.”


Related Links:
National Institutes of Health

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.